Relevant bibliographies by topics / Immunoassay

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Immunoassay'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunoassay.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunoassay"

1

Dasgupta, Amitava, Amanda Peterson, Alice Wells, and Jeffrey K. Actor. "Effect of Indian Ayurvedic Medicine Ashwagandha on Measurement of Serum Digoxin and 11 Commonly Monitored Drugs Using Immunoassays: Study of Protein Binding and Interaction With Digibind." Archives of Pathology & Laboratory Medicine 131, no. 8 (August 1, 2007): 1298–303. http://dx.doi.org/10.5858/2007-131-1298-eoiama.

Full text
Abstract:
Abstract Context.—Ashwagandha, a popular Ayurvedic medicine, is now available in the United States. Alkaloids found in this herb have structural similarity with digoxin. Objective.—To study potential interference of Ashwagandha with serum digoxin measurement by immunoassays. Potential interference was also investigated with immunoassays for 11 other commonly monitored drugs. In addition, interaction of components of Ashwagandha with the Fab fragment of antidigoxin antibody (Digibind) was investigated. Design.—Two different brands of liquid extract and 1 dry powdered form of Ashwagandha were used for this investigation. Aliquots of drug-free serum were supplemented with various concentrations of Ashwagandha and apparent digoxin concentrations were measured by 3 digoxin immunoassays. Mice were fed with Ashwagandha and apparent digoxin concentrations were measured 1 and 3 hours after feeding. Potential interference of Ashwagandha with immunoassays of 11 other drugs was also investigated. Interaction of components of Ashwagandha with Digibind was studied in vitro. Results.—Significant apparent digoxin concentrations were observed both in vitro and in vivo using the fluorescence polarization immunoassay of digoxin, whereas the Beckman and the microparticle enzyme immunoassay digoxin assay demonstrated minimal interference. Immunoassays of 11 other drugs tested were unaffected. When Ashwagandha extract was added to a serum pool containing digoxin, falsely elevated digoxin value was observed with fluorescence polarization immunoassay, but values were falsely lowered when measured by the microparticle enzyme immunoassay. Digibind neutralized digoxin-like immunoreactive components of Ashwagandha in vitro. Conclusions.—Components of Ashwagandha interfered with serum digoxin measurements using immunoassays. Digibind neutralized free digoxin-like immunoreactive components of Ashwagandha.
APA, Harvard, Vancouver, ISO, and other styles
2

Warkentin, Theodore E. "Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies." Hämostaseologie 40, no. 04 (October 22, 2020): 472–84. http://dx.doi.org/10.1055/a-1223-3329.

Full text
Abstract:
AbstractHeparin-induced thrombocytopenia (HIT) is an antibody-mediated hypercoagulable state featuring high thrombosis risk and distinct pathogenesis involving immunoglobulin G-mediated platelet activation. The target of the immune response is a cationic “self” protein, platelet factor 4 (PF4), rendered antigenic by heparin. A key problem is that only a minority of anti-PF4/polyanion antibodies induced by heparin are pathogenic, i.e., capable of causing platelet activation and thereby clinical HIT. Since thrombocytopenia occurs frequently in hospitalized, heparin-treated patients, testing for “HIT antibodies” is common; thus, the problem of distinguishing between pathogenic and nonpathogenic antibodies is important. The central concept is that those antibodies that have platelet-activating properties demonstrable in vitro correlate well with pathogenicity, as shown by platelet activation tests such as the serotonin-release assay (SRA) and heparin-induced platelet activation assay. However, in most circumstances, immunoassays are used for first-line testing, and so it is important for clinicians to appreciate which immunoassay result profiles—in the appropriate clinical context—predict the presence of platelet-activating antibodies (Bayesian analysis). Clinicians with access to rapid, on-demand HIT immunoassays (e.g., particle gel immunoassay, latex immunoturbidimetric assay, chemiluminescent immunoassay) can look beyond simple dichotomous result interpretation (“negative”/“positive”) and incorporate semiquantitative interpretation, where, for example, a strong-positive immunoassay result (or even combination of two immunoassays) points to a greater probability of detecting platelet-activating antibodies, and hence supporting a diagnosis of HIT. Recent recognition of “SRA-negative HIT” has increased the importance of semiquantitative interpretation of immunoassays, given that strong immunoassay reactivity is a potential clue indicating possible HIT despite a (false) negative platelet activation assay.
APA, Harvard, Vancouver, ISO, and other styles
3

Cortez, Samuel, Kyle McNerney, and Ana Maria Arbelaez. "412 Cortisol cut off point to diagnose adrenal insufficiency (AI) using a monoclonal antibody immunoassay." Journal of Clinical and Translational Science 6, s1 (April 2022): 80. http://dx.doi.org/10.1017/cts.2022.239.

Full text
Abstract:
OBJECTIVES/GOALS: AI is diagnosed when peak cortisol level after a cosyntropin stimulation test is <18 mg/dL using polyclonal antibody (pAb) immunoassay. However, the polyclonal assay is being replaced by a specific monoclonal antibody (mAb) immunoassay which yields lower cortisol levels, leading to the over diagnosis of AI and use of unnecessary steroid use. METHODS/STUDY POPULATION: We obtained 36 samples from patients undergoing 1 mcg cosyntropin stimulation tests for diagnosis of AI. Samples were analyzed using pAb immunoassay (Abbott Architect Cortisol), mAb immunoassay (Roche Elecsys Cortisol II), and mass spectrometry (MS). AI was diagnosed if serum cortisol level was <18 using the pAb immunoassay. Measurements by MS and mAb immunoassay were individually used in simple logistic regression models to predict AI. For each model, we calculated a cortisol level corresponding to a 50% probability (median) of AI and used the delta method to determine the standard error and 95% confidence interval of the median. We used receiver operator characteristic (ROC) curve, area under the curve, sensitivity, and specificity to evaluate the potential of the median values as thresholds for each predictor. RESULTS/ANTICIPATED RESULTS: Data showed a mean cortisol level of 17 mcg/dL using the pAb immunoassay, 12 mcg/dL using the mAb immunoassay, and 12.96 mcg/dL using MS. The mean difference in cortisol level between the mAb immunoassay and the pAb immunoassay was 5.12 mcg/dL (p-value <0.01). The ROC curve model indicated an area under the curve of 0.997 with a median value of 11.2 mcg/dL for the mAb immunoassay. This provides a sensitivity of 95%, specificity of 95%, positive predictive value of 95%, and negative predictive value of 94%. This new threshold has a Kappa coefficient of 0.89 when compared to the pAb immunoassay. DISCUSSION/SIGNIFICANCE: New and highly specific mAb immunoassays are being used more widely but yield lower cortisol results. This reflects the need for further studies to determine new cut off points for highly specific cortisol immunoassays. A cut off level of 11.2 mcg/dL would provide a sensitivity of 95% and specificity of 95%.
APA, Harvard, Vancouver, ISO, and other styles
4

Armbruster, D. A., R. H. Schwarzhoff, E. C. Hubster, and M. K. Liserio. "Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening." Clinical Chemistry 39, no. 10 (October 1, 1993): 2137–46. http://dx.doi.org/10.1093/clinchem/39.10.2137.

Full text
Abstract:
Abstract The newest formulation of the Syva EMIT assay for drugs of abuse, EMIT II, and a new immunoassay, OnLine (Roche), utilizing the kinetic interaction of microparticles in solution (KIMS) methodology, RIA tests, and TDx fluorescence polarization immunoassay (FPIA) procedures were compared for marijuana, cocaine, opiates, and barbiturates. Both EMIT II and OnLine immunoassays were performed with a Hitachi 717 analyzer. Calibration curves, the degree of separation between negative and cutoff calibrators, precision, likelihood of carryover from positive to negative samples, and overall ease and speed of analysis were evaluated. RIA and OnLine detected 99% of gas chromatography/mass spectrometry (GC/MS)-confirmed marijuana samples; TDx, 95%; and EMIT II, 88%. All four immunoassays detected approximately 99% of confirmed cocaine-positive urines. RIA, OnLine, and TDx all detected 100% of opiate-confirmed samples; EMIT II, 97%. Barbiturate assays exhibited the greatest disparity, with OnLine and TDx detecting 100% of confirmed positives; EMIT II, 88%; and RIA, 78%. For a variety of reasons, we prefer the fully automated EMIT II and OnLine assays for high-volume urine testing, in comparison with our laboratory's semiautomated RIA tests and the limited-throughput TDx system. The four immunoassays investigated delivered comparable performance in terms of detection rates for GC/MS-confirmed positives for some drugs but not for others.
APA, Harvard, Vancouver, ISO, and other styles
5

Kaufman, Bennett M., and Marion Clower. "Immunoassay of Pesticides: An Update." Journal of AOAC INTERNATIONAL 78, no. 4 (July 1, 1995): 1079–90. http://dx.doi.org/10.1093/jaoac/78.4.1079.

Full text
Abstract:
Abstract Measurement of levels of pesticide residues in foods and crops most often requires extensive cleanup and instrumental techniques such as gas chromatography. Immunoassay measurement techniques, on the other hand, may be used directly on the test portion or require only minimal cleanup. Further refinements of the common antibody–enzyme-based solid-phase assays, such as use of coated magnetic particles, antibody-coated crystals, and continuous-flow devices, have extended the measurement range and applicability of these assays. Likewise, new immunoassays for pesticides have been developed, and existing assays have been refined, optimized, and more completely characterized and validated. In addition to their ability to accurately and reliably measure amounts of residues present in food and crops, immunoassays can be readily used as rapid screening methods for contaminants in field samples. We have previously reviewed much of the work in the area of pesticide immunoassay; this report updates previous information and discusses some new immunoassay techniques.
APA, Harvard, Vancouver, ISO, and other styles
6

Ehm, M., and A. Kappel. "Immunoassays for diagnosis of coagulation disorders." Hämostaseologie 30, no. 04 (2010): 194–201. http://dx.doi.org/10.1055/s-0037-1619055.

Full text
Abstract:
SummaryImmunoassays play a pivotal role in the clinical laboratory. In the coagulation section of the laboratory, they are used as an aid for diagnosis of deep vein thrombosis or pulmonary embolism, thrombophilia screening, or detection of coagulation factor deficiencies, respectively. Enzyme-linked immunosorbent assay (ELISA) and latex agglutination immunoassay technologies are currently most widely used, while Luminescent Oxygen Channeling Immuno - assay (LOCI®) and other chemiluminescencebased immunoassays are emerging technologies for the coagulation laboratory. However, not all immunoassay technologies employed are compatible with the workflow requirements of the coagulation laboratory, and, not all technologies are suitable for detection or quantification of every marker.This review focuses on technical and performance aspects of those immunoassay technologies that are most widely used in the coagulation laboratory, and provides a description of markers that are typically tested by immunoassays.
APA, Harvard, Vancouver, ISO, and other styles
7

Cortez, Samuel, Kyle McNerney, and Ana Maria Arbelaez. "PSAT085 Monoclonal Cortisol Immunoassay Cut Off Point to Diagnose Adrenal Insufficiency (AI)." Journal of the Endocrine Society 6, Supplement_1 (November 1, 2022): A115. http://dx.doi.org/10.1210/jendso/bvac150.234.

Full text
Abstract:
Abstract Objective Adrenal Insufficiency (AI) is diagnosed when the peak cortisol level after a cosyntropin stimulation test is &lt;18 mg/dL using a standard reference (e.g. polyclonal antibody (pAb) immunoassay). However, in most laboratories the polyclonal assay is being replaced by a specific monoclonal antibody (mAb) immunoassay which yields lower cortisol levels, leading to the over diagnosis of AI and unnecessary steroid use. Methods/Study Population We obtained blood samples from 36 patients undergoing 1 mcg cosyntropin stimulation tests for diagnosis of AI. Samples were analyzed using pAb immunoassay (Abbott Architect Cortisol), mAb immunoassay (Roche Elecsys Cortisol II), and mass spectrometry (MS). AI was diagnosed if serum cortisol level was &lt;18 using the pAb immunoassay. Measurements by MS and mAb immunoassay were individually used in simple logistic regression models to predict AI. For each model, we calculated a cortisol level corresponding to a 50% probability (median) of AI and used the delta method to determine the standard error and 95% confidence interval of the median. We used receiver operator characteristic (ROC) curve, area under the curve, sensitivity, and specificity to evaluate the potential of the median values as thresholds for each predictor. Results The ROC curve model indicated an area under the curve of 0.997 with a median value of 11.2 mcg/dL for the mAb immunoassay. This provides a sensitivity of 95%, specificity of 95%, positive predictive value of 95%, and negative predictive value of 94%. This new value has a Kappa coefficient of 0.89 when compared to the pAb immunoassay. When using all the data points throughout the stimulation test, data showed a mean difference in cortisol level between the mAb immunoassay and the pAb immunoassay of 5.12 mcg/dL (p-value &lt;0.01) at any point during the test. Discussion/Significance New and highly specific mAb immunoassays are being used more widely but yield lower cortisol results. This reflects the need for further studies to determine new cut off points for highly specific cortisol immunoassays. A cut off level of 11.2 mcg/dL for the mAb immunoassay would provide a sensitivity of 95% and specificity of 95%. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.
APA, Harvard, Vancouver, ISO, and other styles
8

Darwish, Ibrahim A. "Immunoassay Methods and their Applications in Pharmaceutical Analysis: Basic Methodology and Recent Advances." International Journal of Biomedical Science 2, no. 3 (September 15, 2006): 217–35. http://dx.doi.org/10.59566/ijbs.2006.2217.

Full text
Abstract:
Immunoassays are bioanalytical methods in which the quantitation of the analyte depends on the reaction of an antigen (analyte) and an antibody. Immunoassays have been widely used in many important areas of pharmaceutical analysis such as diagnosis of diseases, therapeutic drug monitoring, clinical pharmacokinetic and bioequivalence studies in drug discovery and pharmaceutical industries. The importance and widespread of immunoassay methods in pharmaceutical analysis are attributed to their inherent specificity, high-throughput, and high sensitivity for the analysis of wide range of analytes in biological samples. Recently, marked improvements were achieved in the field of immunoassay development for the purposes of pharmaceutical analysis. These improvements involved the preparation of the unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The basic methodologies and recent advances in immunoassay methods applied in different fields of pharmaceutical analysis have been reviewed.
APA, Harvard, Vancouver, ISO, and other styles
9

Hashida, Seiichi, Setsuko Ishikawa, Kazuya Hashinaka, Ichiro Nishikata, Shinichi Oka, and Eiji Ishikawa. "Earlier Detection of Human Immunodeficiency Virus Type 1 p24 Antigen and Immunoglobulin G and M Antibodies to p17 Antigen in Seroconversion Serum Panels by Immune Complex Transfer Enzyme Immunoassays." Clinical Diagnostic Laboratory Immunology 7, no. 6 (November 1, 2000): 872–81. http://dx.doi.org/10.1128/cdli.7.6.872-881.2000.

Full text
Abstract:
ABSTRACT For earlier diagnosis of human immunodeficiency virus type 1 (HIV-1) infection, the sensitivities of immune complex transfer enzyme immunoassays for HIV-1 p24 antigen and antibody immunoglobulin G (IgG) to HIV-1 p17 antigen were improved approximately 25- and 90-fold, respectively, over those of the previous immunoassays by performing solid-phase immunoreactions with shaking and increasing the serum sample volumes, and immune complex transfer enzyme immunoassay of antibody IgM to p17 antigen was also performed in the same way as the improved immunoassay of antibody IgG to p17 antigen. By the improved immunoassays, p24 antigen and antibody IgG to p17 antigen were detected earlier in 32 and 53%, respectively, of the HIV-1 seroconversion serum panels tested than before the improvements, and p24 antigen was detected as early as or earlier than HIV-1 RNA by reverse transcriptase-PCR (RT-PCR) in all of the panels tested. In 4 panels out of 19 tested, antibody IgG to p17 antigen or both antibodies IgG and IgM to p17 antigen were detected earlier than p24 antigen and RNA, although the antibody levels declined slightly before their steep increases usually observed after p24 antigen and RNA. Thus, the window period in diagnosis of HIV-1 infection can be shortened by detection of p24 antigen with the improved immunoassay as much as by detection of RNA with RT-PCR and, in some cases, more by detection of antibodies IgG and IgM to p17 antigen with the improved immunoassays than by detections of p24 antigen with the improved immunoassay and RNA with RT-PCR.
APA, Harvard, Vancouver, ISO, and other styles
10

Aslan, Kadir, and Tsehai AJ Grell. "Rapid and Sensitive Detection of Troponin I in Human Whole Blood Samples by Using Silver Nanoparticle Films and Microwave Heating." Clinical Chemistry 57, no. 5 (May 1, 2011): 746–52. http://dx.doi.org/10.1373/clinchem.2010.159889.

Full text
Abstract:
BACKGROUND Cardiovascular diseases are among the leading causes of mortality in developed countries. It is widely recognized that troponin I (TnI) can be used for the assessment of a myocardial infarction. METHODS We investigated the use of the microwave-accelerated and metal-enhanced fluorescence (MA-MEF), a technique based on the combined use of low-power microwave heating, silver nanoparticle films (SNFs), and fluorescence spectroscopy for the detection of TnI from human whole blood samples. SNFs were deposited onto amine-modified glass microscope slides by use of Tollen's reaction scheme and characterized by optical absorption spectroscopy and scanning electron microscopy. The detection of TnI from buffer solutions and human whole blood samples on SNFs was carried out by using fluorescence-based immunoassays at room temperature (control immunoassay, 2 h total assay time) or microwave heating (MA-MEF–based immunoassay, 1 min total assay time). RESULTS We found that the lower limits of detection for TnI from buffer solutions in the control immunoassay and MA-MEF–based immunoassay were 0.1 μg/L and 0.005 μg/L, respectively. However, we were unable to detect TnI in whole blood samples in the control immunoassays owing to the coagulation of whole blood within 5 min of the incubation step. The use of the MA-MEF technique allowed detection of TnI from whole blood samples in 1 min with a lower detection limit of 0.05 μg/L. CONCLUSIONS The MA-MEF–based immunoassay is one of the fastest reported quantitative detection methodos for detection of TnI in human whole blood and has low detection limits similar to those obtained with commercially available immunoassays.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunoassay"

1

Mpoko, C. N. "Immunoassay of thyroxine." Thesis, Manchester Metropolitan University, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.356454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bashirians, George Mamberi. "Metalloporphyrin : catalysed chemiluminescence immunoassay." Thesis, City University London, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.358939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Käppel, Nina Dominique. "Immunoassay-Optimierung für verschiedene Probenmatrices." Berlin Rhombos, 2007. http://deposit.d-nb.de/cgi-bin/dokserv?id=3064298&prov=M&dok_var=1&dok_ext=htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Morgan, L. A. F. "Respiratory syncytial virus antigen immunoassay." Thesis, University of Newcastle Upon Tyne, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.384012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blincko, Stuart. "Novel luminescent compounds for immunoassay." Thesis, City University London, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.255249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

French, Martin Thomas. "Fluorescence immunoassay for cyclosporin A." Thesis, Loughborough University, 1991. https://dspace.lboro.ac.uk/2134/33279.

Full text
Abstract:
Monodansylcadavarine (MDC) was used to synthesise a fluorescent derivative of cyclosporin A and the product of the reaction was isolated by preparative thin layer chromatography (TLC) and purified by high performance liquid chromatography (HPLC). The fluorescent derivative was shown to bind with a polyclonal antibody to cyclosporin A by submitting the derivative for analysis by cyclosporin radioimmunoassay (RIA). However this derivative did not bind with a monoclonal antibody used in a RIA specific for the parent compound. To achieve this fluorescent derivatives were synthesised using cyclosporin-C-hemisuccinate as the staring material with MDC, 4-bromomethyl-7-methoxycoumarin (BMMC), 4-bromomethyl-6,7-dimethoxycoumarin (BMDC) and tetramethyl rhodaminecadavarine (TRC) as the labels. All derivatives were isolated and purified by TLC and HPLC and shown to have antibody binding in the parent compound specific RIA. The fluorescent properties of the derivatives were investigated and the most promising, BMMC and TRC used in the immunoassay development.
APA, Harvard, Vancouver, ISO, and other styles
7

Wilmott, N. J. "Metals as labels in immunoassay." Thesis, Loughborough University, 1985. https://dspace.lboro.ac.uk/2134/25143.

Full text
Abstract:
The basic principles of immunoassay were first reported by Berson and Yalow (1959) and since then it has become an extremely powerful technique in the determination of a broad spectrum of compounds. The power of the technique lying chiefly in the areas of specificity and versatility. The principles of immunoassay are basically straightforward. If the substance of analytical interest is foreign to an animal, typically a rabbit, sheep or goat, injection of that substance into the animal will cause the production of a glycoprotein, known as an antibody (Ab). The antibody produced will have a specificity for the substance that initiated its production, the antigen (Ag). Antigens are generally naturally occur~ng macromolecules, e.g., proteins, polysaccharides, nucleic acids, etc. Smaller molecules, e.g., drugs, hormones, peptides, etc., do not themselves initiate antibody production, but when coupled to a macromolecular carrier, e.g., a protein or a synthetic polypeptide, antibody production may be initiated. The resultant antibodies will react with the carrier linked molecule and also the small molecule alone. A small molecule of this type is known as a hapten.
APA, Harvard, Vancouver, ISO, and other styles
8

Käppel, Nina. "Immunoassay-Optimierung für verschiedene Probenmatrices /." Berlin : Rhombos, 2008. http://deposit.d-nb.de/cgi-bin/dokserv?id=3064298&prov=M&dok_var=1&dok_ext=htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gray, Louise Elizabeth. "A novel electrochemical lateral flow immunoassay." Thesis, University of Strathclyde, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.501682.

Full text
Abstract:
Cardiac surgery with cardiopulmonary bypass (CPB) can trigger systemic inflammatory response syndrome (SIRS) in patients. Pro-inflammatory cytokines lL-6 and IL-8 are reported as particular markers in blood of the inflammatory •espouse to CPB. It would be useful to measure the inflammatory response in the surgical theatre in real/near real time to improve the effectiveness and timings for interventions which may counteract any undesirable inflammatory response. Currently, Enzyme Linked Immunosorbent Assays (ELISAs) and similar systems are used in the central laboratory to measure inflammatory markers however they do not provide results within the appropriate timescale for rapid intervention. Consequently other approaches to assay provision at point of care must be considered. This thesis is concerned with the design, fabrication and characterisation of a prototype, electrochemical, lateral flow system opening a new approach to rapid, point of care (POC), quantitative monitoring of inflammatory markers.
APA, Harvard, Vancouver, ISO, and other styles
10

THOMAS, JENNIFER HODGES. "APPLICATIONS OF MICROBEAD-BASED ELECTROCHEMICAL IMMUNOASSAY." University of Cincinnati / OhioLINK, 2003. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1069337644.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Immunoassay"

1

P, Diamandis Eleftherios, and Christopoulos Theodore K, eds. Immunoassay. San Diego: Academic Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Xu, Chuanlai, Hua Kuang, and Liguang Xu. Food Immunoassay. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-9034-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ngo, T. T., ed. Nonisotopic Immunoassay. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5466-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Weeks, Ian. Chemiluminescence immunoassay. Amsterdam: Elsevier, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1944-, Ngo T. T., ed. Nonisotopic immunoassay. New York: Plenum Press, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wong, Raphael, and Harley Tse, eds. Lateral Flow Immunoassay. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-240-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ngo, T. T., and H. M. Lenhoff, eds. Enzyme-Mediated Immunoassay. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-5012-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

David, Wild, ed. The Immunoassay handbook. 2nd ed. London: Nature Pub. Group, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

David, Wild, ed. The immunoassay handbook. 3rd ed. Amsterdam: Elsevier, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1944-, Ngo T. T., and Lenhoff Howard M, eds. Enzyme-mediated immunoassay. New York: Plenum Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Immunoassay"

1

Debnath, Mousumi, Godavarthi B. K. S. Prasad, and Prakash S. Bisen. "Immunoassay." In Molecular Diagnostics: Promises and Possibilities, 171–80. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-3261-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Smith, Michael L. "Immunoassay." In Principles of Forensic Toxicology, 177–96. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-42917-1_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Töpfer, G. "Immunoassay." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_1547-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Töpfer, G. "Immunoassay." In Springer Reference Medizin, 1226. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_1547.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brandon, David L., and J. Mark Carter. "Immunoassay." In Handbook of Food Safety Engineering, 279–312. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781444355321.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Edwards, Ray. "Radiolabelled immunoassay." In Principles and Practice of Immunoassay, 265–94. London: Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-11234-0_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kricka, Larry, Gary Thorpe, and Richard Stott. "Luminescence immunoassay." In Principles and Practice of Immunoassay, 417–45. London: Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-11234-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Green, Monika, David Barrance, and Paul Hilditch. "Electrometric immunoassay." In Principles and Practice of Immunoassay, 482–514. London: Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-11234-0_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Seare, N. J. "Immunoassay techniques." In Chemical Sensors, 155–67. Dordrecht: Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-010-9154-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Töpfer, G. "Elektrochemilumineszenz-Immunoassay." In Springer Reference Medizin, 761–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_981.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunoassay"

1

Weigl, Bernhard H., Anson Hatch, Andrew E. Kamholz, and Paul Yager. "Novel immunoassay formats for integrated microfluidic circuits: diffusion immunoassays (DIA)." In BiOS 2000 The International Symposium on Biomedical Optics, edited by Raymond P. Mariella, Jr. SPIE, 2000. http://dx.doi.org/10.1117/12.379580.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Augustine, Shancy, Pan Gu, Xiangjun Zheng, Toshikazu Nishida, and Z. Hugh Fan. "Development of All-Plastic Microvalve Array for Multiplexed Immunoassay." In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-38154.

Full text
Abstract:
There is a need for low-cost immunoassays that measure the presence and concentration of multiple harmful agents in one device. Currently, comparable immunoassays employ a one-analyte-per-test format that is time consuming and not cost effective for the requirement of detecting multiple analytes in a single sample. For instance, if a spectrum of harmful agents, including E. coli O157, cholera toxin, and Salmonella typhimurium, should be simultaneously monitored in foods and drinking water, then a one-analyte-per-test would be inefficient. This work demonstrates a platform capable of simultaneous detection of multiple analytes in a single, low-cost, microvalve array-enabled multiplexed immunoassay. This multiplexed immunoassay platform is demonstrated in a prototype COC (cyclic olefin copolymer) device with a 2×3 array in which 6 analytes can be detected simultaneously. In order to contain and regulate the flow of reagents in the multichannel device, an array of microfluidic valves actuated by a thermally expandable material and microfabricated resistors have been developed to direct the flow to the necessary assay sites. The microvalve-based immunoassay is shown to be reliable, easy to operate, and compatible with large-scale integration. The all-plastic microvalves use paraffin wax as the thermally sensitive material which drastically reduces power consumption by latching upon closing so that pulsed power is required only to close and latch the microvalve until it is necessary to re-open the valve. The multiplexed detection scheme has been demonstrated by using three proteins, C reactive protein (CRP) and transferrin, both of which are biomarkers associated with traumatic brain injury (TBI) as well as bovine serum albumin (BSA) as the negative control. Since there are no external bulky pneumatic accessories required to operate/latch the microvalves in the device, this compact, thermally actuated and latching microvalve-enabled multiplexed immunoassay has the potential to realize a portable, low power, battery operated microfluidic device for biological assays.
APA, Harvard, Vancouver, ISO, and other styles
3

Zhou, Xiaoqun, Weihua Hu, and Changming Li. "Fluorescent immunoassay system." In 2013 IEEE Sensors. IEEE, 2013. http://dx.doi.org/10.1109/icsens.2013.6688283.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mantrova, Ekaterina Y., Marina V. Demcheva, Alexander P. Savitsky, and Gely V. Ponomarev. "Universal phosphorescence immunoassay." In OE/LASE'93: Optics, Electro-Optics, & Laser Applications in Science& Engineering, edited by Joseph R. Lakowicz and Richard B. Thompson. SPIE, 1993. http://dx.doi.org/10.1117/12.144715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Krone, Jennifer R., Randall W. Nelson, and Peter W. Williams. "Mass spectrometric immunoassay." In Photonics West '96, edited by Gerald E. Cohn, Steven A. Soper, and C. H. Winston Chen. SPIE, 1996. http://dx.doi.org/10.1117/12.237632.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ishikawa, Tomohiro. "Immunoassay on silicon chip." In 2014 29th Symposium on Microelectronics Technology and Devices (SBMicro). IEEE, 2014. http://dx.doi.org/10.1109/sbmicro.2014.6940079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Khalil, Omar S., G. P. Mattingly, K. Genger, J. Mackowiak, J. Butler, C. Pepe, T. F. Zurek, and N. Abunimeh. "Automated chemiluminescence immunoassay measurements." In OE/LASE'93: Optics, Electro-Optics, & Laser Applications in Science& Engineering, edited by Gerald E. Cohn. SPIE, 1993. http://dx.doi.org/10.1117/12.146728.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yufeng, Yao, Lu Shizhou, Huang Bo, and Zhao Jianwen. "Automated Chemiluminescence Immunoassay Analyzer." In 2010 International Conference on Intelligent Computation Technology and Automation (ICICTA). IEEE, 2010. http://dx.doi.org/10.1109/icicta.2010.180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Walczak, Irene M., Walter F. Love, and Rudolf E. Slovacek. "Sensitive fiber-optic immunoassay." In Optics, Electro-Optics, and Laser Applications in Science and Engineering, edited by Abraham Katzir. SPIE, 1991. http://dx.doi.org/10.1117/12.43859.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khlebtsov, B. N. "SERS-based Platforms for Immunoassay." In 2018 International Conference Laser Optics (ICLO). IEEE, 2018. http://dx.doi.org/10.1109/lo.2018.8435666.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immunoassay"

1

Vann, Douglas C. Toxin Production and Immunoassay Development. 1. Palytoxin. Fort Belvoir, VA: Defense Technical Information Center, March 1988. http://dx.doi.org/10.21236/ada199943.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Waters, L. C., A. Palausky, R. W. Counts, and R. A. Jenkins. Performance of immunoassay kits for site characterization and remediation. Office of Scientific and Technical Information (OSTI), December 1995. http://dx.doi.org/10.2172/204201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Doellgast, George. Ultrasensitive Detection of Toxins Using Immunoassay Amplification. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, February 1992. http://dx.doi.org/10.21236/adb164360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Blake, R., D. Blake, and G. Flowers. A sensitive rapid on-site immunoassay for heavy metal contamination. Office of Scientific and Technical Information (OSTI), May 1996. http://dx.doi.org/10.2172/254372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Carp, Richard I. Fluorescent Immunoassay Development for PrPSc Detection and Antemortem Diagnosis of TSEs. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada455119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dzenitis, J., B. Hindson, M. McBride, A. Makarewicz, B. Henderer, U. Sathyam, S. Smith, et al. Detection of aerosolized biological agents by immunoassay followed by autonomous PCR confirmation. Office of Scientific and Technical Information (OSTI), December 2003. http://dx.doi.org/10.2172/15013780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blake, Diane A. Field-Portable Immunoassay Instruments and Reagents to Measure Chelators and Mobile Forms of Uranium. Office of Scientific and Technical Information (OSTI), June 2005. http://dx.doi.org/10.2172/893458.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Blake, Diane A. Field-Portable Immunoassay Instruments and Reagents to Measure Chelators and Mobile Forms of Uranium. Office of Scientific and Technical Information (OSTI), June 2003. http://dx.doi.org/10.2172/893777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Blake, Diane A. Field-Portable Immunoassay Instruments and Reagents to Measure Chelators and Mobile Forms of Uranium. Office of Scientific and Technical Information (OSTI), June 2001. http://dx.doi.org/10.2172/893872.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Blake, Diane A. Field-Portable Immunoassay Instruments and Reagents to Measure Chelators and Mobile Forms of Uranium. Office of Scientific and Technical Information (OSTI), January 2006. http://dx.doi.org/10.2172/896790.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunoassay' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography